Clinical trial · Observational
UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling
Prostate Cancer Detection by Serum Proteomic Profiling
NCT00355758CI-TRIAL-00003860terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of personnel
Summary
Brief summary (as posted)
: Researchers would like to see if a new test called SELDI (Surface Enhanced Laser Desorption Ionization) analysis can predict biopsy results better than PSA tests.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * For all subjects: * Men 50 years of age or older. * Serum PSA greater than or equal to 2.5 ng/ml and less then or equal to 10.0 ng/ml determined by a measurement within the past six months, and/or digital rectal exam suspicious for prostate cancer as determined by the patient's Urologist. * It has been determined by the treating physician that a prostate biopsy is clinically indicated. * Patients will have already been diagnosed with prostate cancer and scheduled for a radical prostatectomy. For study on treatment effect * Men with clinically localized prostate cancer (total PSA \< 20 ng/ml and clinical T2b or less). * Men with organ confined prostate cancer as determined by final pathologic diagnosis. Exclusion Criteria: * Exclusion criteria for all subjects: * Known prostate cancer or prior treatment for prostate cancer. * Acute prostatitis. * Untreated urinary tract infection. * Presence of Foley catheter or any urethral instrumentation in the previous 48 hours. * Hormonal therapies including LHRH agonists, oral anti-androgens, estrogenic compounds, Proscar or any phytotherapies within the previous 6 months. Exclusion Criteria (for study on treatment effect) * Men with non-organ confined prostate cancer. * Men with detectable serum PSA levels more than 1 months following radical prostatectomy.
References
Publications (0)
Data not yet available
No reference posted for this study.